According to a new report published by Introspective Market Research, Artificial Intelligence in Drug Discovery Market by Technology, Application, and End User, The Global Artificial Intelligence in Drug Discovery Market Size Was Valued at USD 2.13 Billion in 2023 and is Projected to Reach USD 22.70 Billion by 2032, Growing at a CAGR of 30.07%.

Introduction / Market Overview

The Artificial Intelligence in Drug Discovery Market is transforming pharmaceutical research by accelerating the identification, development, and optimization of novel drug candidates. AI-powered platforms leverage machine learning, deep learning, and data analytics to analyze complex biological data, predict molecular behavior, and significantly reduce drug discovery timelines.

Compared to traditional drug discovery approaches, AI-driven solutions offer higher accuracy, lower failure rates, and substantial cost efficiency. These technologies are widely adopted across pharmaceutical companies, biotechnology firms, and academic research institutions to support target identification, lead optimization, drug repurposing, and clinical trial design. Rapid digitalization of healthcare and increasing R&D investments continue to propel market growth.

Growth Driver

A major growth driver of the artificial intelligence in drug discovery market is the increasing demand for faster and more cost-effective drug development processes. Traditional drug discovery methods are time-consuming and expensive, often taking over a decade to bring a drug to market. AI technologies significantly reduce development timelines by improving predictive accuracy and automating data-intensive tasks. Rising prevalence of chronic diseases, growing genomic datasets, and increased pharmaceutical R&D expenditure further accelerate adoption of AI-driven platforms across the global healthcare ecosystem.

Market Opportunity

The market presents significant opportunities through expanding applications of AI in personalized medicine and rare disease drug development. Integration of AI with big data, genomics, and real-world evidence enables precise drug targeting and tailored therapies. Emerging collaborations between technology firms and pharmaceutical companies are creating innovative discovery models. Additionally, increasing adoption of cloud-based AI platforms in emerging economies offers scalable growth potential, positioning AI-driven drug discovery as a critical enabler of next-generation healthcare solutions.

Artificial Intelligence in Drug Discovery Market, Segmentation

Segment A – By Technology

Sub Segment A1: Machine Learning
Sub Segment A2: Deep Learning
Sub Segment A3: Natural Language Processing

Highest Market Share (2023): Machine Learning

Machine learning accounted for the highest market share in 2023 due to its widespread application in predictive modeling, compound screening, and biomarker identification. Its ability to analyze vast datasets and improve outcomes through continuous learning makes it a preferred choice among pharmaceutical and biotech companies. Ongoing advancements and scalability further support its dominant position in the market.

Segment B – By Application

Sub Segment B1: Target Identification
Sub Segment B2: Lead Optimization
Sub Segment B3: Drug Repurposing

Highest Market Share (2023): Target Identification

Target identification leads the application segment as AI tools efficiently analyze biological pathways and disease mechanisms. This accelerates early-stage drug discovery and reduces experimental failures. Increasing focus on precision medicine and complex disease treatment further strengthens the adoption of AI for target identification.

Some of The Leading/Active Market Players Are-

• IBM Corporation (USA)
• Alphabet Inc. – Google DeepMind (USA)
• NVIDIA Corporation (USA)
• Atomwise Inc. (USA)
• BenevolentAI (UK)
• Insilico Medicine (Hong Kong)
• Exscientia plc (UK)
• Schrödinger, Inc. (USA)
• Recursion Pharmaceuticals (USA)
• Microsoft Corporation (USA)

and other active players.

Key Industry Developments

News 1:
In March 2024, leading pharmaceutical companies expanded partnerships with AI technology providers to accelerate drug discovery pipelines.
These collaborations aim to reduce development timelines and improve clinical success rates through advanced predictive modeling and automation.

News 2:
In August 2024, several AI-driven drug discovery platforms launched cloud-based solutions for small and mid-sized biotech firms.
This development enhances accessibility, scalability, and adoption of AI technologies across emerging pharmaceutical markets.

Key Findings of the Study

• Machine learning dominates the technology segment
• Target identification leads application adoption
• North America holds the largest market share
• Rising R&D investments drive market growth
• AI-enabled precision medicine is a key trend